157 related articles for article (PubMed ID: 25905905)
21. Rituximab monotherapy for patients with recurrent primary CNS lymphoma.
Batchelor TT; Grossman SA; Mikkelsen T; Ye X; Desideri S; Lesser GJ
Neurology; 2011 Mar; 76(10):929-30. PubMed ID: 21383331
[No Abstract] [Full Text] [Related]
22. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
23. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.
Strehlow F; Bauer S; Martus P; Weller M; Roth P; Schlegel U; Seidel S; Scheibenbogen C; Korfel A; Kreher S
J Neurooncol; 2016 Aug; 129(1):165-71. PubMed ID: 27294357
[TBL] [Abstract][Full Text] [Related]
24. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
Kikuchi A; Kawada H; Iwaki Y; Machida S; Tsuchiya T; Fukuda R; Hotta T
Rinsho Ketsueki; 2004 Dec; 45(12):1255-7. PubMed ID: 15678918
[TBL] [Abstract][Full Text] [Related]
25. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O
Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061
[TBL] [Abstract][Full Text] [Related]
26. [Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review].
Bai JF; Feng R; Han HX; Wang T; Li JT; Zhang CL; Liu H
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1047-1049. PubMed ID: 32023740
[No Abstract] [Full Text] [Related]
27. Current management of primary central nervous system lymphoma.
Glass J
Chin Clin Oncol; 2017 Aug; 6(4):38. PubMed ID: 28841800
[TBL] [Abstract][Full Text] [Related]
28. Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation.
Cieri N; Di Bartolo O; Corradini P
Curr Opin Hematol; 2015 Nov; 22(6):469-75. PubMed ID: 26390162
[TBL] [Abstract][Full Text] [Related]
29. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
30. Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma.
Wada-Shimosato Y; Ikeda J; Tsujimoto SI; Sasaki K; Yanagimachi M; Kajiwara R; Shiba N; Murata H; Kawahara N; Yamanaka S; Tanoshima R; Ito S
J Pediatr Hematol Oncol; 2019 Oct; 41(7):571-573. PubMed ID: 30124546
[TBL] [Abstract][Full Text] [Related]
31. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
Rastetter W; Molina A; White CA
Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
[TBL] [Abstract][Full Text] [Related]
32. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Pitini V; Arrigo C; Righi M
Cancer; 2004 Dec; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
[No Abstract] [Full Text] [Related]
33. Secondary central nervous system involvement by follicular lymphoma: case report and review of the literature.
Grupka NL; Seinfeld J; Ryder J; Lillehei KO; Kleinschmidt-Demasters BK
Surg Neurol; 2006 Jun; 65(6):590-4. PubMed ID: 16720183
[TBL] [Abstract][Full Text] [Related]
34. [Magnetic resonance as initial screening diagnosis of secondary involvement of central nervous system in NHL diffuse large B cell lymphoma].
Oliver AC; Irigoin V; Sgarbi N; Peixoto A; Turcatti P; Diaz L; Zunino J
Rev Fac Cien Med Univ Nac Cordoba; 2018 Jun; 75(2):67-71. PubMed ID: 30273529
[TBL] [Abstract][Full Text] [Related]
35. Primary central nervous system lymphoma: current state of anti-CD20 therapy and appraisal of reported response criteria.
Siegal T
J Clin Neurosci; 2014 May; 21(5):709-15. PubMed ID: 24725453
[TBL] [Abstract][Full Text] [Related]
36. Intra-CSF rituximab for lymhomatous meningitis.
Chamberlain MC; Glantz MJ
J Clin Oncol; 2007 Oct; 25(28):4508-9; author reply 4509-11. PubMed ID: 17906219
[No Abstract] [Full Text] [Related]
37. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
38. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
[No Abstract] [Full Text] [Related]
39. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
